Will some pent-up deal pressure amp up a biotech rally?
Over the last 6 weeks we’ve seen the Nasdaq biotech index surge 21%, an early-stage company just upsized its IPO and stuck to the range …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
